BRPI0913586A2 - combinação, uso de combinação, método para tratar, inibir ou prevenir uma doença ou condição. - Google Patents

combinação, uso de combinação, método para tratar, inibir ou prevenir uma doença ou condição.

Info

Publication number
BRPI0913586A2
BRPI0913586A2 BRPI0913586A BRPI0913586A BRPI0913586A2 BR PI0913586 A2 BRPI0913586 A2 BR PI0913586A2 BR PI0913586 A BRPI0913586 A BR PI0913586A BR PI0913586 A BRPI0913586 A BR PI0913586A BR PI0913586 A2 BRPI0913586 A2 BR PI0913586A2
Authority
BR
Brazil
Prior art keywords
combination
inhibiting
disease
treating
preventing
Prior art date
Application number
BRPI0913586A
Other languages
English (en)
Inventor
Antonio Celestino Fernandes
Constance Elizabeth Medlen
Stephen Leivers
Original Assignee
Pfeinsmith S A Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfeinsmith S A Pty Ltd filed Critical Pfeinsmith S A Pty Ltd
Publication of BRPI0913586A2 publication Critical patent/BRPI0913586A2/pt
Publication of BRPI0913586A8 publication Critical patent/BRPI0913586A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BRPI0913586A 2008-06-05 2009-06-04 combinação, e, uso de uma combinação. BRPI0913586A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200804901 2008-06-05
PCT/IB2009/052366 WO2009147635A1 (en) 2008-06-05 2009-06-04 Fulvic acid and antibiotic combination

Publications (2)

Publication Number Publication Date
BRPI0913586A2 true BRPI0913586A2 (pt) 2015-10-27
BRPI0913586A8 BRPI0913586A8 (pt) 2018-03-13

Family

ID=40887008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913586A BRPI0913586A8 (pt) 2008-06-05 2009-06-04 combinação, e, uso de uma combinação.

Country Status (8)

Country Link
US (1) US8445452B2 (pt)
EP (1) EP2317998B1 (pt)
CN (1) CN102099027B (pt)
BR (1) BRPI0913586A8 (pt)
PL (1) PL2317998T3 (pt)
RU (1) RU2505295C2 (pt)
WO (1) WO2009147635A1 (pt)
ZA (1) ZA201008680B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914966D0 (en) * 2009-08-27 2009-09-30 Natracine Uk Ltd Fulvic acid compositions and their use
KR20140135813A (ko) * 2012-03-07 2014-11-26 나트라신 유케이 리미티드 다제 내성 박테리아의 억제 또는 치료를 위한 풀브산과 항생제 조합
CN113813304A (zh) * 2020-06-18 2021-12-21 陈信行 腐植酸山苍子复方及其制程
CN111616358A (zh) * 2020-06-20 2020-09-04 田劭军 一种用于提高免疫力的组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204368A (en) * 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
JP4700808B2 (ja) * 1998-10-08 2011-06-15 プフェインスミス・リミテッド フルボ酸、および種々の状態の処置におけるその使用
CN1120820C (zh) * 1999-08-12 2003-09-10 河南省科学院生物研究所 健植液肥
CN101437509B (zh) * 2006-05-02 2012-03-14 皮费恩史密斯有限公司 酸性组合物
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方

Also Published As

Publication number Publication date
PL2317998T3 (pl) 2016-11-30
RU2505295C2 (ru) 2014-01-27
ZA201008680B (en) 2012-03-28
CN102099027B (zh) 2012-12-12
BRPI0913586A8 (pt) 2018-03-13
CN102099027A (zh) 2011-06-15
US8445452B2 (en) 2013-05-21
EP2317998B1 (en) 2016-04-20
WO2009147635A1 (en) 2009-12-10
EP2317998A1 (en) 2011-05-11
US20110207687A1 (en) 2011-08-25
RU2010154511A (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0814958A2 (pt) Compostos de indazol ou indol, composição, e, método para preparar uma composição.
BRPI0906607A2 (pt) Agentes de coalescência eficazes.
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0816175A2 (pt) Composições adequadas para tratamento de doença, distúrbio ou condição da espinha.
BRPI0907230A2 (pt) composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
BRPI0923856A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar uma doença ou distúrbio.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PFEINSMITH LTD (ZA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements